Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1995-05-19
2000-03-28
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241841, 4242371, 435 691, A61K 3909, A61K 3900, C12P 2106
Patent
active
060428384
ABSTRACT:
Mucosal administration, particularly intranasally, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with cholera toxin B subunit, provides protection in animals against pneumococcal colonization and systemic infection. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
REFERENCES:
patent: 4873890 (1989-10-01), Clancey et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5476929 (1995-12-01), Briles et al.
Bixten et al. Synthetic Vaccines, vol. 1, pp. 39-71, 1987.
Van de Wiggert et al, Infection and Immunity, 59:2750-57, 1991.
Fontanges et al. Rev. Fr. Allergol 17: 35-41, 1977 Abstract only.
Garcia et al. FTMS Microbiol Lett. 108:163-167, 1993, Abstract only.
Kurl et al., Acta Path Microbiol Immunol. 93: 401-405, 1985 Abstract only.
McDaniel et al., Infect & Immunity 59: 222-228, 1991.
Talkington et al. Infection & Immunity 59: 1285-1289, 1991.
Germie et al., Novel Vaccine Strategies: Mucosal Immunization, Adjuvants and Genetic Approaches Oct. 1993, Abstract only.
Bessen et al. Joun. of Immunology 1990, vol. 145: 1251-1256.
Wu et al. Infection & Immunity 61: 314-327, 1993.
Anonymous. Centers for Disease Control HIV/AIDS Surveillance Report. 1991; Aug.: 1-18.
Fraser DW. What Are Our Bacterial Disease Problems. In: JB Robbins, Hill JC, Sadoff JC ed. Bacterial Vaccines. New York: 1982: xix-xxiv.
Berman S, McIntosh K. Selective Primary Health Care: Strategies For Control Of Disease In The Developing World. XXI Acute Respiratory Infections. Rev. Infect. Dis. 1985; 7:647-491.
Greenwood BM, Greenwood AM, Bradley AK, Tulloch S, Hayes R, Oldfield FSJ. Deaths In Infancy And Early Childhood In A Well Vaccinated, Rural, West African Population. Ann. Trop. Pediatr. 1987; 7:91-99.
Spika JS, Munshi MH, Wojtyaniak B, Sack DA, Hossain A., Rahman M, Saha SK, Acute Lower Respiratory Infections: A Major Cause Of Death In Children In Bangladesh. Ann. Trop. Pediatr. 1989; 9: 33-39.
Bale JR, Etiology And Epidemiology Of Acute Respiratory Tract Infections In Children In Developing Countries. Rev. Infect. Dis. 1990; 12 (Suppl. 8): S861-S1083.
Munoz R, Musser JM, Crain M, Briles DE, Marton A, Parkinson AJ, Sorensen U, Tomasz A. Geographic Distribution Of Penicillin-Resistant Clones Of Streptococcus Pneumoniae: Characterization By Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme Analysis. Clinic. Infect. Dis. 1992; 15:112-118.
Marton A, Gulyas M, Munoz R, Tomasz A. Extremely High Incidence Of Antibiotic Resistance In Clinical Isolates Of Streptococcus Pneumoniae: In Hungary. J. Infect. Dis. 1991; 163: 542-548.
Klugman KP. Pneumococcal Resistance To Antibiotics. Clin. Microbiol. Rev. 1990.
Gray BM, Converse GM III, Dillon HC. Epidemiologic Studies Of Streptococcus Pneumoniae In Infants: Acquisition, Carriage, And Infection During The First 24 Months Of Life. J. Infect. Dis. 1980; 142: 923-933.
Gray BM, Converse GM III, Huhta N., Johnston RB Jr., Pichichero ME, Schiffman G. Dillon HC Jr. Antibody Response To Pneumococcal Carriage. J. Infect. Dis. 1981; 142:312-318.
Hendley JO, Sande MA, Stewart PM, et al. Spread Of Streptococcus Peumoniae In Families. I. Carriage Rates And Distribution Of Types. J. Infect. Dis. 1975; 132-55.
Smillie WG, Warnock GH, White HJ. A Study Of A Type 1 Pneumococcus At State Hospital At Worchester Massachusetts. Am. J. Pub. Hlth 1938; 28: 293-302.
Smillie WG, A Study Of An Outbreak Of Type II Pneumococcal Pneumonia In The Veterans Administration Hospital At Bedford, Massachusetts, Am. J. Hyg. 1936; 24:522-535.
Gratten M, Naraqi S, Hansman D. High Prevalence Of Penicillin-Insensitive Pneumococci In Port Moresby, Paupa New Guinea. Lancet 1980; 11:192-195.
DeMaria TF, McGhee RB, Lim DJ. Rheumatoid Factor In Otitis Media With Effusion. Arch Otolaryngol. 1984; 110:279-280.
Bohr V, Rasmussen N, Hansen B, Gade A, Kjersem H, Johsen N. Paulson O. Pheumococcal meningitis: An Evaluation Of Prognostic Factors In 164 Cases Based On Mortality And On A Study Of Lasting Sequelae. J. Infect. Dis. 1985; 10:143-157.
Klein Jo. The Epidemiology Of Pneumococcal Diseases In Infants And Children. Rev. Infect. Dis. 1981; 3: 246-.
Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser WD, Schlech WFI. Pneumococcal Vaccine Efficacy In Selected Populations In The United States. Ann. Intern. Med. 1986; 104: 1-6.
Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells, Margolis, Adair RK, Clemmens JD., Protective Efficacy Of Polyvalent Pneumococcal Polysaccharide Vaccine. N. Engl. J. Med 1991; 325: 1453-1460.
Cowan MJ, Ammann AJ, Wara DW, Howie VM, Schultz L, Doyle N, Kaplan M, Pneumococcal Polysaccharide Immunization In Infants And Children. Pediatrics 1978; 62: 721-727.
Gotschlich EC, Goldschneider I, Lepow ML, Gold R. The Immune Response To Bacterial Polysaccharides In Man. Antibodies In Human Diagnosis And Therapy. New York: Raven, 1977: 391-402.
Barbour ML, Mayon-White RT, Crook DW, Coles C, Moxon ER. The Influence Of Haemophilus Influenzae Type B (Hib) Conjugate Vaccine (PRP-T) On Oropharyngeal Carriage Of Hib In Infants Under 12 Months Of Age. ICAAC Abstracts 1993: 33:175.
Chiu SS, Greenberg PD, Marcy SM, Wong VK, Chang SJ, Chiu CY, Ward JI. Mucosal Antibody Responses In Infants Following Immunization With Haemophilus Influenzae Pediatric Res. Abstracts 1994; 35 : 10A.
Fallon MT, Reinhard MK, Gray BM, Davis TW, Lindsey JR. Inapparent Streptococcus Pneumoniae Yype 35 Infections In Commercial Rats And Mice. Laboratory Animal Science 1988; 38:129-.
Douglas RM, DH, Miles HB, Paton JC, Pneumococcal carriage and Type-Specific Antibody Failure Of A 14-Valent Vaccine To Reduce Carriage In Healthy Children. American Journal of Diseases of Children 1986; 140 : 1183-1185.
Douglas RM, Miles HB. Vaccination Against Streptococcus Pneumoniae In Childhood: Lack Of Demonstrable Benefit In Young Australian Children. Journal of Infectious Diseases 1984; 149:861-869.
Mestecky J. The Common Mucosal Immune System And Current Strategies For Induction Of Immune Response In External Secretions. J. Clin. Immunol. 1987; 7:265-276.
Croitoru K, Bienenstock J. Characteristics And Functions Of Mucosa-Associated Lymphoid Tissue. In: PL Ogra, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J ed. Handbook of Mucosal Immunology. San Diego, CA: Academic Press, Inc., 1994: 141-149.
Bienenstock J, Johnston N, Perey DY. Bronchial Lymphoid Tissue. I. Morphologic Characteristics. Lab. Invest. 1973; 28: 686-692.
Bienenstock J. Johnston N. Perey DY. Bronchial Lymphoid Tissue. II. Functional Characteristics. Lab. Invest. 1973; 693-698.
Pabst R. Is BALT a Major Component Of The Human Lung Immune System? Immunology Today 1992; 13:119-122.
Kuper CF, Koomstra PJ, Hameleers DMH, Biewenga J, Spit BJ, Duijvestijn AM, van Breda Vriesman PJC, Sminia T. The Role Of Nasopharyngeal Lymphoid Tissue. Immunol. Today 1992; 13: 219-224.
Wu H-Y, Russell MW. Induction Of Mucosal Immunity By Intranasal Application Of A Streptococcal Surface Protein Antigen With The Cholera Toxin B Subunit. Infection and Immunity 1993; 61:314-322.
Russell. MW, Wu H-Y. Distribution Persistence, And Recall Of Serum And Salvary Antibody Responses To Peroral Immunization With Protein Antigen I/II Of Streptococcus Mutants Coupled To The Cholera Toxin B Subunit. Infection and Immunity 1991; 59:4061-4070.
Elson CO, Ealding W. Generalized Systemic And Mucosal Immunity In Mice After Mucosal Stimulation With Cholera Toxin. J. Immunol. 1984; 132:2736-2741.
Elson CO. Cholera Toxin And Its Subunits As Potential Oral Adjuvants. Curr. Topics Microbiol. Immunol. 1989; 146:29-33.
Lycke N, Holmgren J. Strong Adjuvant Properties Of Cholera Toxin On Gut Mucosal Immune Responses To Orally Presented Antigens. Immunology 1986; 59:301-308.
Wilson AD, Stokes CR, Bourme FJ. Adjuvant Effect Of Cholera Toxin On The Mucosal Immune Response To Soluble Proteins. Differences Between Mouse Strains And Protein Antigens. Scan
Briles David E.
Wu Hong-Yin
Frommer William S.
Housel James C.
Kowalski Thomas J.
Swartz Rodney P.
UAB Research Foundation
LandOfFree
immunogenic compositions for mucosal administration of pneumococ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with immunogenic compositions for mucosal administration of pneumococ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and immunogenic compositions for mucosal administration of pneumococ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1323808